Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

@article{Kelly2011EffectsOT,
  title={Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.},
  author={Deanna Lynn Kelly and David Alan Gorelick and Robert R. Conley and Douglas Lee Boggs and Jared Allen Linthicum and Fang Liu and Stephanie S. Feldman and Mary Patricia Ball and Heidi J . Wehring and Robert Patrick McMahon and Marilyn A Huestis and Stephen J. Heishman and Kimberly R Warren and Robert W. Buchanan},
  journal={Journal of clinical psychopharmacology},
  year={2011},
  volume={31 1},
  pages={86-91}
}
Weight gain is a major adverse effect of several second-generation antipsychotic medications. Rimonabant is a cannabinoid-1 receptor antagonist that promotes weight loss in the general population. We conducted a 16-week, double-blind, placebo-controlled study of rimonabant (20 mg/d) in people with schizophrenia or schizoaffective disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria, who were clinically stable on second-generation antipsychotics… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…